IQVIA United States’ Post

🌟 As we step into 2024, the landscape of biopharma launches is undergoing significant shifts. Policy changes, economic pressures, and launch suppression have created an increasingly complex environment. But fear not! Our experts at IQVIA have their crystal balls out, and they’re making some bold predictions for the year ahead. #PharmaPredictions #LifeSciences #AgileBrands #2024outlook

2023 was a year of uncertainty and corrections. 2024 continues to have a high level of ambiguity. My colleagues and I have made some predictions regarding successful HCP engagement and customer experience strategies in the year ahead.  #pharmaindustry #CX #CSO #Omnichannel #Agility  Read the full blog here: https://lnkd.in/ecvb2xRU

Have you been thinking about what trends are going to drive HCP engagement and customer experience in 2024? Check out IQVIA's BOLD PREDICTIONS!

How important is trust in #pharma marketing? According to Graphite Digital, trust is the "key factor in digital HCP engagement." The problem? Too many HCPs don't trust pharma. Focusing on customer centricity as a necessary part of digital transformation is one way to foster trust. Holly Mitchell, Client Strategist at Graphite Digital, shares five tips for accomplishing your digital goals while putting the customer first. #pharmamarketing

It’s an exciting time for the #pharma industry, where advanced algorithms can bring #HCP data, patient data, and #analytics together in a compliant way, accelerating insights that ultimately help physicians find lifesaving treatment options. Read our new Agile Brand Promotion blog post to learn how to build a modern, data-driven HCP engagement strategy for your organization: https://bit.ly/3T3kv0Q

This is a topic Lime has been talking about for years—life science marketers have to go beyond our product’s profile and create compelling customer experiences that shift beliefs and behaviors and help achieve their healthcare goals. No matter if it’s a pending launch or something already in market, we must start with the customer segment’s journey to understand pain points and needs, uncover insights, and then consider what we do and say. "In increasingly crowded drug markets, a strong clinical profile is no longer enough to ensure a distinctive launch...Focusing too narrowly on clinical value often leads companies to neglect a powerful driver of launch success: the customer experience." We recommend reading more from the highly relevant article below by McKinsey & Company. (Tag a life science colleague in the comments who would appreciate this.) #Customerexperience #CX #productlaunch #pharma #customers #lifescience #lifesciencemarketing #strategy #marketing #lime #LimeLights

Customer experience is crucial for product adoption across all industries, and pharma is no exception. How can the pharma industry enhance the customer experience journey based on HCPs’ preferences? Find out in our latest infographic: https://hubs.la/Q02K0s6q0 ⭐ Key takeaways from the data ⭐ - Winning websites: HCPs value up-to-date, trusted, and free information. Younger HCPs are more likely to value pharma sites as "critical" than older HCPs. - Digital advertising: Quality trumps quantity! Pharma can leverage data to enhance digital communications and elevate user experiences. - Patient resources: HCPs desire more patient management guidelines, case studies, and resources. Pharma companies have an excellent opportunity here. - Data and insights: Many HCPs are keen on learning measurement methods, presenting a chance for pharma to better leverage these insights.

I am sure that if you are in a brand team, from the agency that supports them or a medic in the approvals process, then you are already painfully aware of the significant increase in the amount of content pharma produces, but let's just take a moment to digest the year on year growth in content hosted on Promomats as published in #veeva Pulse reports 2018-2019 76% 2019-2020 65% 2020-2021 37% 2021-2022 20% 2022-2023 20% (expected - pending next pulse report publication - thanks for the heads up Emma Hyland) This growth is being driven by the move to digital, rise of omnichannel, proliferation of channels and the need for personalised needs based content and I don't think anyone believes it can be sustained if we stick with the current ways of working. In response we have seen almost every pharma initiate some form of globally driven strategy to improve the content development process, from modular content, to content intelligence, content re-use and centralised content production factories.....BUT.....are any of these solutions landing for local markets? If not why not and what needs to be done to make it work and enable us to deliver the personalised need based content our customers deserve? Join myself, Huw Jenkins, andrew binns, Sioned Preece and Gülru Yigit as we debate, discuss and take questions from the audience on this critical topic. 13th March 3.30pm BST https://lnkd.in/eXxXfQGv

Success in the healthcare industry often hinges on bringing together the right expertise quickly to develop pragmatic and connected solutions to strategic challenges. Learn how our embedded Brand Directors empower teams to overcome regulatory hurdles, streamline launch strategies, and create impactful customer experiences—offering expertise without the risk: https://bit.ly/3SxtqXO #AvalereHealth #EmbeddedConsulting

Success in the healthcare industry often hinges on bringing together the right expertise quickly to develop pragmatic and connected solutions to strategic challenges. Learn how our embedded Brand Directors empower teams to overcome regulatory hurdles, streamline launch strategies, and create impactful customer experiences—offering expertise without the risk: https://bit.ly/3SxtqXO #AvalereHealth #EmbeddedConsulting